Dave Dai analyst JEFFERIES

Currently out of the existing stock ratings of Dave Dai, 83 are a BUY (100%).

Dave Dai

Work Performance Price Targets & Ratings Chart

Analyst Dave Dai, currently employed at SMBC NIKKO,

Dave Dai’s has documented 4 price targets and ratings displayed on 5 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ACET, Adicet Bio at 31-Mar-2022.

Wall Street Analyst Dave Dai

Analyst best performing recommendations are on INBX (INHIBRX ).
INBX Inhibrx  JNCE Jounce Therapeutics MGNX MacroGenics NKTX Nkarta  ACET Adicet Bio

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

3 months 18 days ago
(23-Jul-2024)

4/6 (66.67%)

$4.74 (21.29%)

118

Buy

$46

$29.79 (183.78%)

$46

1 years 8 months 3 days ago
(07-Mar-2023)

0/4 (0%)

$22.03 (91.91%)

Buy

$40

$9.67 (31.88%)

2 years 7 months 25 days ago
(16-Mar-2022)

0/1 (0%)

$17.23 (75.67%)

Buy

$53

$21.73 (69.49%)

3 years ago
(10-Nov-2021)

1/2 (50%)

$10.05 (23.40%)

271

Buy

$60

$41.65 (226.98%)

$30

3 years 29 days ago
(12-Oct-2021)

1/2 (50%)

$19.48 (75.48%)

78

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Dave Dai?

On 2022

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?